| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 0.2 | 0.3 |
| Gross profit | 0.2 | 0.2 |
| Profit before tax | -1.9 | -2.2 |
| Net income | -1.9 | -2.2 |
| EPS (diluted, $ a share) | $-0.05 | $-0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -29.8% |
|---|---|
| Gross margin | 92.1% |
10-Q filed with the SEC, OTC: PETV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
PetVivo Holdings, Inc.: key numbers
- Share price
- $0.5150Close, Nov 16
- Market cap
- $19.8M
- Shares outstanding
- 38.54MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from PetVivo Holdings, Inc.
All →PetVivo Holdings Leadership Change
PetVivo Holdings announced the appointment of Jaime K. Pickett to its Board of Directors, effective September 22, 2026, filling a vacancy created by the resignation of Diane Levitan. Dr. Pickett brings over 20 years of experience in veterinary healthcare and executive leadership, including former roles as CEO and President of Hannah Pet Hospitals.
PetVivo Holdings Leadership Change
Joseph Jasper resigned from the Board of Directors of PetVivo Holdings, Inc., effective September 22, 2026. To fill the vacancy, the Board appointed Michael K. Handley, a life sciences executive with over 25 years of experience in biotechnology and medical devices, as a non-employee director. Handley's background includes raising over $700 million in capital and supporting more than 80 global product launches.